ING Groep NV increased its holdings in shares of Catalent Inc (NYSE:CTLT) by 24.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,047 shares of the company’s stock after acquiring an additional 3,960 shares during the quarter. ING Groep NV’s holdings in Catalent were worth $824,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of CTLT. Zions Bancorporation bought a new stake in Catalent during the third quarter worth $100,000. First Bank & Trust lifted its holdings in Catalent by 54.2% during the fourth quarter. First Bank & Trust now owns 3,764 shares of the company’s stock worth $155,000 after acquiring an additional 1,323 shares during the period. Fortaleza Asset Management Inc. bought a new stake in Catalent during the third quarter worth $164,000. Advisor Group Inc. lifted its holdings in Catalent by 1.3% during the second quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after acquiring an additional 65 shares during the period. Finally, CAPROCK Group Inc. bought a new stake in Catalent during the fourth quarter worth $203,000. Institutional investors and hedge funds own 99.82% of the company’s stock.
Shares of Catalent Inc (CTLT) opened at $41.58 on Thursday. The stock has a market capitalization of $5,440.74, a price-to-earnings ratio of 25.51, a price-to-earnings-growth ratio of 2.34 and a beta of 1.47. The company has a debt-to-equity ratio of 2.66, a current ratio of 2.22 and a quick ratio of 1.78. Catalent Inc has a one year low of $27.48 and a one year high of $47.87.
In related news, Director Uwe Roehrhoff acquired 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were bought at an average cost of $39.22 per share, for a total transaction of $294,150.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider John R. Chiminski sold 181,458 shares of the business’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. Insiders own 1.70% of the company’s stock.
A number of brokerages recently commented on CTLT. Royal Bank of Canada set a $48.00 price target on Catalent and gave the stock a “buy” rating in a report on Monday, February 5th. Zacks Investment Research lowered Catalent from a “buy” rating to a “hold” rating in a research note on Thursday, January 18th. Goldman Sachs Group started coverage on Catalent in a research note on Wednesday, January 24th. They issued a “buy” rating and a $50.00 target price on the stock. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th. Finally, Piper Jaffray Companies boosted their target price on Catalent from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, November 7th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Catalent presently has an average rating of “Buy” and a consensus price target of $45.60.
ILLEGAL ACTIVITY WARNING: “Catalent Inc (CTLT) Position Increased by ING Groep NV” was first published by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://weekherald.com/2018/02/15/catalent-inc-ctlt-position-increased-by-ing-groep-nv.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.